Nanoprodrugs of NSAIDs inhibit the growth of U87-MG glioma cells

Journal of Nanomaterials

Volumn 2010, Issue , 2010, Pages

  Yu, John S ^a   Lee, Bong Seop ^a   Yuan, Xiangpeng ^a   Xu, Qijin ^a   Ko, Minhee K ^a   Nalla, Aruna K ^a   Frankiel, Ilana ^a   Shear, Talia ^a   Black, Keith L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER AGENTS; CELL COUNTING; CELLULAR UPTAKE; EQUIMOLAR CONCENTRATIONS; GLIOMA CELLS; INDOMETHACIN; MALIGNANT CELLS; NAPROXENS; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; PRODRUGS; PROPIDIUM IODIDE; SPONTANEOUS EMULSIFICATION;

CELL PROLIFERATION; EMULSIFICATION; GROWTH KINETICS;

DRUG PRODUCTS;

EID: 77951983418     PISSN: 16874110     EISSN: 16874129     Source Type: Journal    
DOI: 10.1155/2010/583970     Document Type: Article

References (52)

1. Mitchell J. A., Warner T. D., Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy British Journal of Pharmacology 1999 128 6 1121 1132
2. Kargman S., Charleson S., Cartwright M., Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts Gastroenterology 1996 111 2 445 454
3. Dempke W., Rie C., Grothey A., Schmoll H.-J., Cyclooxygenase-2: a novel target for cancer chemotherapy? Journal of Cancer Research and Clinical Oncology 2001 127 7 411 417
4. Fournier D. B., Gordon G. B., COX-2 and colon cancer: potential targets for chemoprevention Journal of Cellular Biochemistry 2000 34 supplement 97 102
5. Fosslien E., Molecular pathology of cyclooxygenase-2 in neoplasia Annals of Clinical Laboratory Science 2000 30 1 3 21
6. Shrieve D. C., Alexander E. III, Black P. M., Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and longterm outcome Journal of Neurosurgery 1999 90 1 72 77
7. Deininger M. H., Weller M., Streffer J., Mittelbronn M., Meyermann R., Patterns of cyclooxgenase-1 and -2 expression in human gliomas in vivo Acta Neuropathologica 1999 98 3 240 244
8. Joki T., Heese O., Nikas D. C., Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398 Cancer Research 2000 60 17 4926 4931
9. Patti R., Gumired K., Reddanna P., Sutton L. N., Phillips P. C., Reddy C. D., Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib Cancer Letters 2002 180 1 13 21
10. Shono T., Tofilon P. J., Bruner J. M., Owolabi O., Lang F. F., Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations Cancer Research 2001 61 11 4375 4381
11. Keller J. J., Giardiello F. M., Chemoprevention strategies using NSAIDs and COX-2 inhibitors Cancer Biology Therapy 2003 2 4, supplement 1 S140 S149
12. Gupta R. A., DuBois R. N., Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 Nature Reviews Cancer 2001 1 1 11 21
13. Umar A., Viner J. L., Anderson W. F., Hawk E. T., Development of COX inhibitors in cancer prevention and therapy American Journal of Clinical Oncology 2003 26 4, supplement 2 S48 S57
14. Harris R. E., Beebe-Donk J., Doss H., Burr Doss D., Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review) Oncology Reports 2005 13 4 559 583
15. Lin D. W., Nelson P. S., The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma Clinical Prostate Cancer 2003 2 2 119 126
16. Mann J. R., DuBois R. N., Cyclooxygenase-2 and gastrointestinal cancer Cancer Journal 2004 10 3 145 152
17. Basler J. W., Piazza G. A., Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention The Journal of Urology 2004 171 2 S59 S63
18. Sabichi A. L., Lippman S. M., COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer Seminars in Oncology 2004 31 21, supplement 7 36 44
19. Chuang H.-C., Kardosh A., Gaffney K. J., Petasis N. A., Schnthal A. H., COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro Molecular Cancer 2008 7, article 38
20. Marx J., Anti-inflammatories inhibit cancer growthbut how? Science 2001 291 5504 581 582
21. Elder D. J., Halton D. E., Hague A., Paraskeva C., Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression Clinical Cancer Research 1997 3 10 1679 1683
22. Jiang H., Lin J. J., Su Z.-Z., Goldstein N. I., Fisher P. B., Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression Oncogene 1995 11 12 2477 2486
23. Andrews J., Djakiew D., Krygier S., Andrews P., Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells Cancer Chemotherapy and Pharmacology 2002 50 4 277 284
24. Yao M., Zhou W., Sangha S., Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer Clinical Cancer Research 2005 11 4 1618 1628
25. Janssen A., Maier T. J., Schiffmann S., Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment European Journal of Pharmacology 2006 540 13 24 33
26. Khwaja F., Allen J., Lynch J., Andrews P., Djakiew D., Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein Cancer Research 2004 64 17 6207 6213
27. Whittle B. J. R., Gastrointestinal effects of nonsteroidal anti-inflammatory drugs Fundamental Clinical Pharmacology 2003 17 3 301 313
28. Dannhardt G., Kiefer W., Cyclooxygenase inhibitorscurrent status and future prospects European Journal of Medicinal Chemistry 2001 36 2 109 126
29. Tammara V. K., Narurkar M. M., Crider A. M., Khan M. A., Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen Pharmaceutical Research 1993 10 8 1191 1199
30. Bonina F. P., Puglia C., Barbuzzi T., In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac European Journal of Pharmaceutical Sciences 2001 14 2 123 134
31. Chandrasekaran S., Al-Ghananeem A. M., Riggs R. M., Crooks P. A., Synthesis and stability of two indomethacin prodrugs Bioorganic Medicinal Chemistry Letters 2006 16 7 1874 1879
32. Siskou I. C., Rekka E. A., Kourounakis A. P., Chrysselis M. C., Tsiakitzis K., Kourounakis P. N., Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties Bioorganic Medicinal Chemistry 2007 15 2 951 961
33. Velzquez C. A., Praveen Rao P. N., Citro M. L., Keefer L. K., Knaus E. E., O 2 -acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies Bioorganic Medicinal Chemistry 2007 15 14 4767 4774
34. Huang B., Zhang J., Hou J., Chen C., Free radical scavenging efficiency of Nano-Se in vitro Free Radical Biology Medicine 2003 35 7 805 813 (Pubitemid 37329484)
35. Cheong J. N., Tan C. P., Man Y. B. C., Misran M., -tocopherol nanodispersions: preparation, characterization and stability evaluation Journal of Food Engineering 2008 89 2 204 209
36. Shafiq S., Shakeel F., Talegaonkar S., Ahmad F. J., Khar R. K., Ali M., Development and bioavailability assessment of ramipril nanoemulsion formulation European Journal of Pharmaceutics and Biopharmaceutics 2007 66 2 227 243 (Pubitemid 46667230)
37. Kuo F., Subramanian B., Kotyla T., Wilson T. A., Yoganathan S., Nicolosi R. J., Nanoemulsions of an anti-oxidant synergy formulation containing gamma tocopherol have enhanced bioavailability and anti-inflammatory properties International Journal of Pharmaceutics 2008 363 1-2 206 213
38. Lee B.-S., Yuan X., Xu Q., Stimuli-responsive antioxidant nanoprodrugs of NSAIDs International Journal of Pharmaceutics 2009 372 1-2 112 124
39. Lee B. S., Yuan X., Xu Q., Preparation and characterization of antioxidant nanospheres from multiple -lipoic acid-containing compounds Bioorganic Medicinal Chemistry Letters 2009 19 6 1678 1681
40. Heckert E. G., Karakoti A. S., Seal S., Self W. T., The role of cerium redox state in the SOD mimetic activity of nanoceria Biomaterials 2008 29 18 2705 2709
41. Bouchemal K., Brianon S., Perrier E., Fessi H., Bonnet I., Zydowicz N., Synthesis and characterization of polyurethane and poly(ether urethane) nanocapsules using a new technique of interfacial polycondensation combined to spontaneous emulsification International Journal of Pharmaceutics 2004 269 1 89 100
42. Bouchemal K., Brianon S., Perrier E., Fessi H., Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation International Journal of Pharmaceutics 2004 280 1-2 241 251
43. Chouinard F., Kan F. W. K., Leroux J.-C., Foucher C., Lenaerts V., Preparation and purification of polyisohexylcyanoacrylate nanocapsules International Journal of Pharmaceutics 1991 72 3 211 217
44. Fessi H., Piusieux F., Devissaguet J. Ph., Ammoury N., Benita S., Nanocapsule formation by interfacial polymer deposition following solvent displacement International Journal of Pharmaceutics 1989 55 1 R1 R4
45. Macklis J. D., Madison R. D., Progressive incorporation of propidium iodide in cultured mouse neurons correlates with declining electrophysiological status: a fluorescence scale of membrane integrity Journal of Neuroscience Methods 1990 31 1 43 46
46. Weiner M., Bernstein I. L., Adverse Reactions to Drug Formulation Agents 1989 New York, NY, USA Marcel Dekker
47. Gad S. C., Drug Safety Evaluation 2002 chapter 13.8 New York, NY, USA John Wiley Sons
48. Matsumura Y., Maeda H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Research 1986 46 12 6387 6392
49. Couvreur P., Vauthier C., Nanotechnology: intelligent design to treat complex disease Pharmaceutical Research 2006 23 7 1417 1450
50. Yuan F., Dellian M., Fukumura D., Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Research 1995 55 17 3752 3756
51. Torchilin V. P., Recent advances with liposomes as pharmaceutical carriers Nature Reviews Drug Discovery 2005 4 2 145 160
52. Hobbs S. K., Monsky W. L., Yuan F., Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proceedings of the National Academy of Sciences of the United States of America 1998 95 8 4607 4612